FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1585339973> ?p ?o ?g. }

• W1585339973 abstract "The potassium channel blockers 4-aminopyridine (AP) and 3,4-diaminopyridine (DAP) increase nerve conduction in demyelinated nerve fibers, and have been proposed as a symptomatic therapy for people with multiple sclerosis (MS).To determine the efficacy and safety of aminopyridines for neurological deficits in MS people.We searched CENTRAL (Issue 2, 2002), MEDLINE (January 1966-July 2002), EMBASE (1974-July 2002), and the Cochrane MS Group's Specialised Register. We hand searched bibliographic references from retrieved studies and recent MS symposia reports, and contacted known studies' investigators.We included trials fulfilling all following criteria: randomised controlled trials (RCTs); adults with MS, out of exacerbation; AP or DAP treatment versus placebo; clinical endpoints.We identified 26 potentially pertinent studies. Three reviewers independently extracted data and assessed trial quality from 17 full-paper studies.Six studies (eight publications, 198 participants, all crossover trials) were considered. Five studies assessed the efficacy of AP versus placebo, one compared DAP with active placebo. Treatment duration ranged from hours to six months. Median quality score of the studies was 3. Heterogeneity of outcome assessment and absence of information on individual study periods allowed quantitative pooling of results for few categorical variables. Of the 198 treated patients, there were six major side effects: one acute encephalopathy, three episodes of confusion, and two seizures. Three studies (54 patients) assessed manual muscle testing, with 29 patients (54%) improving in at least one muscular district during study treatment versus four patients (7%) during placebo (odds ratio [OR] 14.5, 95% confidence interval [CI] 4.7-43.7). Nine out of 54 participants (17%) improved in ambulation during study treatment versus none during placebo (p<0.001). A lower EDSS score was found in 13/198 participants during study treatment (7%) versus none during placebo (p<0.001). No improvement in neuropsychological tests was found in three trials assessing cognitive function. Finally, 47/136 MS people (35%) felt better when receiving the study drug, against 7(5%) on placebo (OR 9.7, 95% CI 4.3-22.0).Currently available information allows no unbiased statement about safety or efficacy of aminopyridines for treating MS symptoms. Furthermore, we could not obtain any data on three unpublished RCTs (more than 300 participants). We conclude that publication bias remains a pervasive problem in this area, and that until the results of these unpublished studies are available to the scientific community, no confident estimate of effectiveness of aminopyridines in the management of MS symptoms is possible." @default.
• W1585339973 created "2016-06-24" @default.
• W1585339973 creator A5008338463 @default.
• W1585339973 creator A5029507779 @default.
• W1585339973 creator A5034580501 @default.
• W1585339973 creator A5058699032 @default.
• W1585339973 creator A5062180127 @default.
• W1585339973 date "2002-10-21" @default.
• W1585339973 modified "2023-09-27" @default.
• W1585339973 title "Aminopyridines for symptomatic treatment in multiple sclerosis" @default.
• W1585339973 cites W1964879289 @default.
• W1585339973 cites W1967440018 @default.
• W1585339973 cites W1969198078 @default.
• W1585339973 cites W1975879668 @default.
• W1585339973 cites W1979693042 @default.
• W1585339973 cites W1983897914 @default.
• W1585339973 cites W1986215651 @default.
• W1585339973 cites W1987499148 @default.
• W1585339973 cites W1991834239 @default.
• W1585339973 cites W1994772430 @default.
• W1585339973 cites W1994805414 @default.
• W1585339973 cites W1995192578 @default.
• W1585339973 cites W2012184244 @default.
• W1585339973 cites W2014912839 @default.
• W1585339973 cites W2036523727 @default.
• W1585339973 cites W2039736060 @default.
• W1585339973 cites W2045167317 @default.
• W1585339973 cites W2049169550 @default.
• W1585339973 cites W2049769020 @default.
• W1585339973 cites W2050442028 @default.
• W1585339973 cites W2060029300 @default.
• W1585339973 cites W2062369227 @default.
• W1585339973 cites W2102696978 @default.
• W1585339973 cites W2117268408 @default.
• W1585339973 cites W2125702143 @default.
• W1585339973 cites W2131177331 @default.
• W1585339973 cites W2131876585 @default.
• W1585339973 cites W2158796001 @default.
• W1585339973 cites W2164777277 @default.
• W1585339973 cites W2320853752 @default.
• W1585339973 cites W2325038063 @default.
• W1585339973 doi "https://doi.org/10.1002/14651858.cd001330" @default.
• W1585339973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12804404" @default.
• W1585339973 hasPublicationYear "2002" @default.
• W1585339973 type Work @default.
• W1585339973 sameAs 1585339973 @default.
• W1585339973 citedByCount "46" @default.
• W1585339973 countsByYear W15853399732012 @default.
• W1585339973 countsByYear W15853399732013 @default.
• W1585339973 countsByYear W15853399732014 @default.
• W1585339973 countsByYear W15853399732015 @default.
• W1585339973 countsByYear W15853399732016 @default.
• W1585339973 countsByYear W15853399732017 @default.
• W1585339973 countsByYear W15853399732018 @default.
• W1585339973 countsByYear W15853399732019 @default.
• W1585339973 countsByYear W15853399732020 @default.
• W1585339973 countsByYear W15853399732021 @default.
• W1585339973 countsByYear W15853399732022 @default.
• W1585339973 crossrefType "journal-article" @default.
• W1585339973 hasAuthorship W1585339973A5008338463 @default.
• W1585339973 hasAuthorship W1585339973A5029507779 @default.
• W1585339973 hasAuthorship W1585339973A5034580501 @default.
• W1585339973 hasAuthorship W1585339973A5058699032 @default.
• W1585339973 hasAuthorship W1585339973A5062180127 @default.
• W1585339973 hasBestOaLocation W15853399732 @default.
• W1585339973 hasConcept C126322002 @default.
• W1585339973 hasConcept C142454548 @default.
• W1585339973 hasConcept C142724271 @default.
• W1585339973 hasConcept C156957248 @default.
• W1585339973 hasConcept C1862650 @default.
• W1585339973 hasConcept C197934379 @default.
• W1585339973 hasConcept C204787440 @default.
• W1585339973 hasConcept C27081682 @default.
• W1585339973 hasConcept C2780922449 @default.
• W1585339973 hasConcept C44249647 @default.
• W1585339973 hasConcept C535046627 @default.
• W1585339973 hasConcept C67774102 @default.
• W1585339973 hasConcept C71924100 @default.
• W1585339973 hasConcept C82789193 @default.
• W1585339973 hasConcept C83743174 @default.
• W1585339973 hasConceptScore W1585339973C126322002 @default.
• W1585339973 hasConceptScore W1585339973C142454548 @default.
• W1585339973 hasConceptScore W1585339973C142724271 @default.
• W1585339973 hasConceptScore W1585339973C156957248 @default.
• W1585339973 hasConceptScore W1585339973C1862650 @default.
• W1585339973 hasConceptScore W1585339973C197934379 @default.
• W1585339973 hasConceptScore W1585339973C204787440 @default.
• W1585339973 hasConceptScore W1585339973C27081682 @default.
• W1585339973 hasConceptScore W1585339973C2780922449 @default.
• W1585339973 hasConceptScore W1585339973C44249647 @default.
• W1585339973 hasConceptScore W1585339973C535046627 @default.
• W1585339973 hasConceptScore W1585339973C67774102 @default.
• W1585339973 hasConceptScore W1585339973C71924100 @default.
• W1585339973 hasConceptScore W1585339973C82789193 @default.
• W1585339973 hasConceptScore W1585339973C83743174 @default.
• W1585339973 hasLocation W15853399731 @default.
• W1585339973 hasLocation W15853399732 @default.
• W1585339973 hasLocation W15853399733 @default.
• W1585339973 hasOpenAccess W1585339973 @default.
• W1585339973 hasPrimaryLocation W15853399731 @default.

• next